Roivant Sciences (NASDAQ:ROIV – Get Free Report) and Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.
Profitability
This table compares Roivant Sciences and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
| Rigel Pharmaceuticals | 116.30% | 22.95% | 17.19% |
Valuation and Earnings
This table compares Roivant Sciences and Rigel Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roivant Sciences | $7.53 million | 3,511.88 | -$299.77 million | ($0.53) | -69.09 |
| Rigel Pharmaceuticals | $294.28 million | 2.87 | $367.02 million | $16.32 | 2.80 |
Rigel Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations for Roivant Sciences and Rigel Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roivant Sciences | 1 | 2 | 10 | 1 | 2.79 |
| Rigel Pharmaceuticals | 1 | 2 | 3 | 0 | 2.33 |
Roivant Sciences presently has a consensus price target of $46.55, indicating a potential upside of 27.10%. Rigel Pharmaceuticals has a consensus price target of $65.50, indicating a potential upside of 43.29%. Given Rigel Pharmaceuticals’ higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Roivant Sciences.
Insider & Institutional Ownership
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats Roivant Sciences on 11 of the 15 factors compared between the two stocks.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
